EGFR and neoplasm: Consequently, pyrotinib inhibits autophosphorylation, blocks the activation of downstream signaling pathways, and inhibits tumor cell growth.[9] Clinically, EGFR/HER2 occurs in various mutation types, which may influence the formation of different EGFR/HER2 dimers, inducing different responses to lapatinib or pyrotinib.